Purdue Pharma to Shut Down as Landmark Opioid Case Reaches Final Chapter

Purdue Pharma, the maker of the powerful opioid OxyContin, is set to be dissolved following a federal judge’s approval of its criminal sentence, marking a major turning point in one of the most consequential corporate cases tied to the U.S. opioid crisis.

The ruling by a U.S. federal court finalizes a long-running case brought by the U.S. Department of Justice, allowing the company to move forward with a sweeping settlement aimed at resolving thousands of lawsuits filed by states, local governments, and victims. Madeline Cox Arleo delivered the sentence, which effectively clears the path for Purdue to exit bankruptcy and cease operations.

Under the agreement, Purdue will pay billions of dollars in penalties linked to its earlier guilty plea for misleading regulators and fueling opioid sales through illegal marketing practices. However, only a fraction; about $225 million is expected to be collected directly by the federal government, with the bulk of funds tied to a broader settlement designed to address the nationwide addiction crisis.

As part of the restructuring, the company will be replaced by a new entity, widely reported as a public-benefit organization focused on combating opioid addiction and expanding treatment access. This transition is intended to redirect remaining corporate resources toward addressing the epidemic that has claimed hundreds of thousands of lives in the United States since the late 1990s.

The settlement also includes significant financial contributions from the Sackler family, Purdue’s former owners, who have agreed to pay billions over time. In return, they are expected to receive protection from future civil lawsuits related to the opioid crisis; a provision that has drawn sharp criticism from victims and advocacy groups.

During court proceedings, emotional testimonies from victims and families highlighted the devastating human toll of opioid addiction, with many arguing that financial penalties alone fall short of delivering justice. Some critics also noted that no individual executives are facing criminal charges as part of the resolution.

Legal experts say the dissolution of Purdue Pharma represents an unprecedented outcome for a major pharmaceutical company, signaling a broader shift toward holding corporations accountable for public health crises, even as debates continue over whether the settlement goes far enough.